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Abstract CCN2, also known as connective tissue growth factor
(CTGF) is a transcriptional target of TGF-β signaling. Unlike its
original name (“CTGF”) suggested, CCN2 is not an actual
growth factor but a matricellular protein that plays an important
role in fibrosis, inflammation and connective tissue remodeling
in a variety of diseases, including cancer. In pancreatic ductal
adenocarcinoma, CCN2 signaling induces stromal infiltration
and facilitates a strong tumor-stromal interaction. In many types
of cancer, CCN2 overexpression has been associated with poor
outcome. CMS4 (Consensus Molecular Subtype 4) is a recently
identified aggressive colorectal cancer subtype, that is character-
ized by up-regulation of genes involved in epithelial-to-
mesenchymal transition, TGF-β signaling, angiogenesis, com-
plement activation, and extracellular matrix remodeling. In addi-
tion, a high influx of stromal fibroblasts contributes to the
mesenchymal-like gene expression profile of this subtype.
Furthermore, compared with the other three CMS groups,
CMS4 tumors have the worst prognosis. Based on these obser-
vations, we postulated that CCN2 might contribute to colorectal
cancer progression, especially in the CMS4 subtype. This review
discusses the available literature on the role of CCN2 in colorec-
tal cancer, with a focus on the ‘fibrotic subtype’ CMS4.
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Abbreviations
CMS Consensus Molecular Subtype
CRC Colorectal cancer
CCN2 CCN-family protein 2
CTGF Connective tissue growth factor
EMT Epithelial-to-mesenchymal transition
PDAC Pancreatic ductal adenocarcinoma
TGF-β Transforming Growth Factor β
Introduction
Colorectal cancer (CRC) is one of the most common causes of
cancer-related mortality in the Western world (Siegel et al.
2016). CRC is a highly heterogeneous disease. Traditional
CRC staging takes into account the depth of invasive growth,
the histological differentiation grade and the presence of metas-
tases in lymph nodes and in distant organs. More recently, the
CRC Subtyping Consortium has identified four Consensus
Molecular Subtypes (CMS) based on integrative analysis of
molecular data linked to tumor phenotype and clinical features
(Guinney et al. 2015). CMS1 tumors are often microsatellite
instable and are characterized by strong activation of immune
pathways. This subtype responds best to immune checkpoint
inhibition, presumably due to a deficient mismatch repair path-
way, which leads to a high mutational load and the generation
of tumor-specific neo-antigens (Le et al. 2015; de Weger et al.
2012). Tumors of CMS2 are characterized by a high level of
copy number alterations, epithelial differentiation, up-
regulation of WNT and MYC targets, and chromosomal insta-
bility. CMS3 tumors are likely to harbor activating mutations in
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KRAS, and show amarked deregulation ofmetabolic pathways;
CMS3 tumors also display high-level chromosomal instability
(CIN). CMS4 tumors are characterized by high expression of
genes involved in epithelial-to-mesenchymal transition (EMT),
Transforming Growth Factor β (TGF-β) signaling, angiogen-
esis and extracellular matrix remodeling. CMS4 tumors also
exhibit a high density of tumor-associated fibroblasts.
Importantly, CMS4 tumors have a poorer prognosis compared
with the other subtypes, due to an increased likelihood of dis-
tant relapse (Guinney et al. 2015; Becht et al. 2016).
CCN2, is well-known for its involvement in connective tis-
sue remodeling in various diseases, including cancer. CCN2 is a
transcriptional target of TGF- β, that binds growth factors, ex-
tracellular matrix protein, and cell surface molecules, including
integrins, therebymodulating signaling activity inmultiple path-
ways (reviewed by (Lau 2016; Cicha and Goppelt-Struebe
2009)). In preclinical studies of pancreatic ductal adenocarcino-
ma (PDAC), a cancer typewith particularly strong tumor-stroma
interaction and stromal infiltration, CCN2 has been identified as
a major determinant of tumor growth and metastasis, and as a
valid therapeutic target (Dornhofer et al. 2006; Bennewith et al.
2009). A phase 1/2 trial with neo-adjuvant xanti-CCN2 (“anti-
CTGF”) antibody treatment (FG3019) in locally advanced
PDAC is underway (NCT02210559). Furthermore, CTGF over-
expression has been associated with poor prognosis in several
tumor types, including B-cell acute lymphoblastic leukemia
(Boag et al. 2007; Sala-Torra et al. 2007), breast cancer (Chien
et al. 2011), gastric cancer (Liu et al. 2008), glioma (Xie et al.
2004), melanoma (Hutchenreuther et al. 2015), pancreatic can-
cer (Bennewith et al. 2009) and prostate cancer (Yang et al.
2005). Based on the findings in other cancer types, and on the
notion that CMS4 tumors are stroma-rich and have a poor prog-
nosis, we suggest that CCN2 could also play a role in the fibrotic
response that characterizes CMS4 CRC.
CCN2 and colorectal cancer progression
TGF-β acts as a tumor suppressor in colorectal cancer initia-
tion, by inhibiting excessive cell proliferation. However, in
later stages of tumor development, TGF-β plays a crucial
pro-metastatic role and its expression is associated with worse
outcome (Massague 2008; Calon et al. 2012). mRNA and
protein levels of CCN2, a well-known transcriptional target
of TGF-β, were found to be increased in more advanced
Duke’s and TNM stages of CRC (Ladwa et al. 2011).
CRC canmetastasize via blood or lymphatic vessels. TGF-β
signaling has been implicated in formation of metastases and
facilitation of secondary organ colonization (Calon et al. 2012).
By recruiting myofibroblasts to the invasive tumor front via
TGF-β signaling, tumor cells facilitate their own invasion and
metastatic spread (Massague 2008). A similar role has been
proposed for CCN2 based on the observed correlation of
CCN2 expression with α-smooth muscle actin expression in
ileal carcinoids, an endocrine carcinoma that is extremely rich
in fibrosis (Cunningham et al. 2010). Furthermore, conditioned
medium from colon cancer cells can stimulate CCN2 expres-
sion in peritoneal fibroblasts (Yokota et al. 2016).
Although the contribution of lymphangiogenesis to CRC
progression is currently unknown, it does correlate with poor
Fig. 1 High CCN2(/CTGF) expression is associated with poor prognosis
Kaplan Meier curves showing the disease-free (a) and overall (b) survival
of the CCN2(/CTGF)-high (upper 25 %) and CCN2(/CTGF)-low (lower
75 %) expression subgroups. The inset shows the expression of CCN2(/
CTGF) in the high and low subgroups
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prognosis (Sundlisaeter et al. 2007). We recently identified
involvement of CCN2 not only in fibrotic matrix remodeling
but also in lymphangiogenesis downstream of TGF-β in ex-
perimental kidney fibrosis (Kinashi et al., unpublished data).
TGF-β activates CCN2 expression through canonical
pSmad2/3 signaling, but depending on cell type and context
also through RhoA, Ras, and MEKK 1/2 (reviewed by (Cicha
and Goppelt-Struebe 2009)). The TGF-β pathway regulates
lymphangiogenesis and stromal infiltration and activation,
which may in part be mediated by induction of its transcrip-
tional target CCN2.
CCN2 and prognosis of colorectal cancer
Several research groups have studied the relationship between
CCN2 expression and CRC prognosis, with conflicting
results. Lin and others (2005; 2011) performed immunohisto-
chemical analyses of CCN2 expression in primary CRC, and
found that high CCN2 levels were associated with a decreased
risk of peritoneal metastasis and with significantly higher
disease-free and overall survival. In other studies however,
CCN2 levels were higher in more advanced CRC stages
(Ladwa et al. 2011; Guo et al. 2015), and activation of the
TAZ-AXL-CCN2 axis in CRC was associated with higher
stage, higher grade and poorer survival in CRC patients
(Yuen et al. 2013; Zhang et al. 2016). Using gene expression
data from 800 primary CRC samples (from publically avail-
able data sets used by Guinney et al. (2015)), we found that
relapse-free survival as well as overall survival of CRC
patients with high CCN2 expression (N = 200; top-25 %)
was significantly shorter than in CRC patients with low
CCN2 expression (N = 600; lower 75 %), p < 0.001 and
p = 0.011, respectively (Fig. 1a, b). Taken together, the data
on CCN2 expression in relation to prognosis in CRC remains
inconclusive. To resolve this issue, new studies are needed
that couple the use of well-validated anti-CCN2 antibodies
on immunohistochemistry with RNA analyses in thoroughly
annotated large cohorts of CRC patients.
CCN2 expression has been linked to drug resistance in
several types of cancer (Tsai et al. 2014; Lai et al. 2011; Yin
et al. 2010). It has also been suggested that CCN2 expression
contributes to therapy resistance in CRC, since overexpression
of CCN2 induced resistance to radiotherapy (combined with
simvastatin) in colorectal cancer cell lines, whereas CCN2
knockdown increased the radiosensitivity (Lim et al. 2015).
Data on this subject are very limited however, and more re-
search is needed to elucidate the role of CCN2 in the response
to standard chemotherapy and targeted therapy in CRC.
CCN2 and CMS4
In a collection of 2476 primary CRC samples (Guinney et al.
2015), we compared the expression levels of CCN2(/CTGF)
mRNA between the four CMS of CRC. This revealed that
expression is particularly high in CMS4 (Fig. 2a).
Furthermore, CMS4 tumors were strongly enriched in the
CCN2(/CTGF)-high group, while the canonical subtypes
(CMS2, CMS3) were enriched in the CCN2(/CTGF)-low
Fig. 2 CCN2(/CTGF) and CMS (a) CCN2(/CTGF) mRNA expression
in the consensus molecular CRC subtypes. (b) Analysis of the percentage
CMS1–4 contributing to the CCN2(/CTGF)-high and CCN2(/CTGF)-
low subgroups. The genomics analysis and visualization application R2
(http://r2.amc.nl) was used to analyze the expression of CCN-2(/CTGF)
in the four consensus molecular subtypes (CMS1–4)
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subgroup (Fig. 2b). Interestingly, CCN2 was identified as an
upstream activating regulator of a 19 gene-based risk profile
that predicts poor CRC prognosis and benefit from adjuvant
chemotherapy (Kim et al. 2014). Considering the strong as-
sociation between CCN2 expression and the CMS4 colorectal
cancer subtype, CCN2 could be an interesting target for
therapy.
Conclusion
The available data on the role of CCN2(/CTGF) in colorectal
cancer progression and prognosis is limited, and in part con-
tradictory. The high expression of CCN2(/CTGF)x in CMS4
colorectal cancer and its established role in tissue fibrosis war-
rant further investigation to establish the possible value of
xCCN2(/CTGF) as a marker and potential therapeutic target
in CRC, especially in the aggressive mesenchymal subtype.
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